This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Highlights in Early Stage, 1L Metastatic, and Refractory Melanoma"

478 views
June 7, 2024

Chapters

NADINA Study & Neoadjuvant Therapy

00:00

1L Metastatic: Triplet Immunotherapy & TIL

05:13

Refractory Melanoma: TIL & Viral Therapies

07:01

Survivability & Therapy Sequencing Insights

09:23

Comments 0
Login to view comments. Click here to Login